BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

2005989 citationsJournal Articlebronze Open Access

Authors

Mingzhao Xing

William H. Westra

Ralph P. Tufano

Yoram Cohen

Eli Rosenbaum

Kerry J. Rhoden · John B. Pierce Laboratory

Kathryn A. Carson · Johns Hopkins University

Vasily Vasko · MedStar Washington Hospital Center

О. С. Ларін

Giovanni Tallini

Abstract

In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence. Therefore, BRAF mutation may be a useful molecular marker to assist in risk stratification for patients with PTC.

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment S100 Proteins and Annexins Pituitary Gland Disorders and Treatments

UN Sustainable Development Goals

No poverty

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 90, Issue 12, pp. 6373-6379

DOI: 10.1210/jc.2005-0987

Field-Weighted Citation Impact: 20.55